{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:58:49Z","timestamp":1792277929946,"version":"4.4.0"},"reference-count":20,"publisher":"Siapec Servizi Srl","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-791","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T16:51:46Z","timestamp":1663865506000},"page":"288-294","source":"Crossref","is-referenced-by-count":51,"title":["In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay"],"prefix":"10.32074","volume":"114","author":[{"given":"Caterina","family":"Fumagalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Betella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ranghiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Guerini-Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Bonaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Rappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Vacirca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Barberis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2022,9]]},"reference":[{"key":"10.32074\/1591-951X-791_ref1","doi-asserted-by":"crossref","unstructured":"Global Burden of Disease 2019 Cancer Collaboration; Kocarnik JM, Compton K, Dean FE, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 Cancer Groups From 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol 2022;8:420-444. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6987","DOI":"10.1001\/jamaoncol.2021.6987"},{"key":"10.32074\/1591-951X-791_ref2","unstructured":"I numeri del cancro in Italia 2021 \u2013 https:\/\/www.aiom.it\/wp-content\/uploads\/2021\/10\/2021_NumeriCancro_web.pdf"},{"key":"10.32074\/1591-951X-791_ref3","doi-asserted-by":"crossref","unstructured":"Lisio MA, Fu L, Goyeneche A, et al. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci 2019;20:952. https:\/\/doi.org\/10.3390\/ijms20040952","DOI":"10.3390\/ijms20040952"},{"key":"10.32074\/1591-951X-791_ref4","doi-asserted-by":"crossref","unstructured":"Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22:1721-1731. https:\/\/doi.org\/10.1016\/S1470-2045(21)00531-3","DOI":"10.1016\/S1470-2045(21)00531-3"},{"key":"10.32074\/1591-951X-791_ref5","doi-asserted-by":"crossref","unstructured":"Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 2019;381:2403-2415. https:\/\/doi.org\/10.1056\/NEJMoa1909707","DOI":"10.1056\/NEJMoa1909707"},{"key":"10.32074\/1591-951X-791_ref6","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381:2391-2402. https:\/\/doi.org\/10.1056\/NEJMoa1910962","DOI":"10.1056\/NEJMoa1910962"},{"key":"10.32074\/1591-951X-791_ref7","doi-asserted-by":"crossref","unstructured":"Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381:2416-2428. https:\/\/doi.org\/10.1056\/NEJMoa1911361","DOI":"10.1056\/NEJMoa1911361"},{"key":"10.32074\/1591-951X-791_ref8","doi-asserted-by":"crossref","unstructured":"Swisher EM, Aghajanian C, O\u2019Malley DM, et al. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA\/GOG-3005 study. Gynecol Oncol 2022;164:245-253. https:\/\/doi.org\/10.1016\/j.ygyno.2021.12.003","DOI":"10.1016\/j.ygyno.2021.12.003"},{"key":"10.32074\/1591-951X-791_ref9","unstructured":"FDA Lynparza: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208558s013lbl.pdf (accessed on 10 May 2022)"},{"key":"10.32074\/1591-951X-791_ref10","unstructured":"EMA Lynparza: https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-lynparza-ii-35-ii-36_en.pdf (accessed on 10 May 2022)"},{"key":"10.32074\/1591-951X-791_ref11","unstructured":"AIFA Lynparza: https:\/\/www.aifa.gov.it\/documents\/20142\/961234\/Determina_194-2022_Lynparza.pdf (accessed on 10 May 2022)"},{"key":"10.32074\/1591-951X-791_ref12","doi-asserted-by":"crossref","unstructured":"Vergote I, Gonz\u00e1lez-Mart\u00edn A, Ray-Coquard I, et al. European experts consensus: BRCA\/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol 2022;33:276-287. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.013","DOI":"10.1016\/j.annonc.2021.11.013"},{"key":"10.32074\/1591-951X-791_ref13","doi-asserted-by":"crossref","unstructured":"Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 2015;11:1137-1154. https:\/\/doi.org\/10.1158\/2159-8290.Cd-15-071","DOI":"10.1158\/2159-8290.CD-15-0714"},{"key":"10.32074\/1591-951X-791_ref14","doi-asserted-by":"crossref","unstructured":"Wagener-Ryczek S, Merkelbach-Bruse S, Siemanowski J. Biomarkers for homologous recombination deficiency in cancer. J Pers Med 2021;11:612. doi:10.3390\/jpm11070612","DOI":"10.3390\/jpm11070612"},{"key":"10.32074\/1591-951X-791_ref15","doi-asserted-by":"crossref","unstructured":"Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"10.32074\/1591-951X-791_ref16","unstructured":"AmoyDiagnostics. Available online: http:\/\/www.amoydiagnostics.com\/productDetail_46.htlm"},{"key":"10.32074\/1591-951X-791_ref17","doi-asserted-by":"crossref","unstructured":"Fumagalli C, Betella I, Rappa A, et al. Tumor BRCA Testing in epithelial ovarian cancers: past and future-five-years\u2019 single-institution experience of 762 consecutive patients. Cancers 2022;14:1638. https:\/\/doi.org\/10.3390\/cancers14071638","DOI":"10.3390\/cancers14071638"},{"key":"10.32074\/1591-951X-791_ref18","doi-asserted-by":"crossref","unstructured":"Weichert W, Lukashchuk N, Yarunin A, et al. An evaluation of the performance of molecular assays to identify homologous recombination deficiency-positive tumours in ovarian cancer Int J Gynecol Cancer 2021;31:A366.","DOI":"10.1136\/ijgc-2021-ESGO.645"},{"key":"10.32074\/1591-951X-791_ref19","doi-asserted-by":"crossref","unstructured":"Pujade-Lauraine E, Christinat Y, D\u2019incalci M, et al. 201 Homologous recombination deficiency testing in advanced ovarian cancer: description of the ENGOT HRD European initiative. Int J Gynecol Cancer 2021;31:A208.","DOI":"10.1136\/ijgc-2021-ESGO.356"},{"key":"10.32074\/1591-951X-791_ref20","unstructured":"SGO 2022 Annual Meeting| March 18-21, 2022 https:\/\/sgomtg22.us2.pathable.com\/meetings\/virtual\/nRerYfh2bMwvczGuJ"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:27:08Z","timestamp":1730813228000},"score":1,"resource":{"primary":{"URL":"https:\/\/old.pathologica.it\/article\/view\/791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,8]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-791","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]},"article-number":"3"}}